Hong Kong Seeks Australian Advice On Regulating Drug Industry
This article was originally published in PharmAsia News
Executive Summary
Hong Kong health authorities have elicited the help of Australian drug experts to guide it in setting manufacturing standards for Hong Kong pharmaceuticals. The move follows a series of scandals in which tainted or unregistered drugs reached the market. In one incident, executives of Marching Pharmaceuticals were arrested after they recalled products without notifying the health department. The department's director reported the action at a meeting of the Pharmaceutical Society of Hong Kong. The head of that group said its members see no problem with the regulations already in place. (Click here for more
You may also be interested in...
Hong Kong Regulators Review Manufacturing, Supply Chain Regulations In Wake Of Tainted Products Leading To Six Deaths
HONG KONG - A review of Hong Kong's drug regulatory infrastructure could lead to more stringent requirements for pharmaceutical manufacturers, importers and distributors
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.